Last reviewed · How we verify
Qulipta (ATOGEPANT)
Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain.
Qulipta (atogepant) is a small molecule calcitonin gene-related peptide receptor antagonist developed by Abbvie. It targets the calcitonin gene-related peptide type 1 receptor to prevent migraine episodes in adults. Qulipta was FDA-approved in 2021 and is currently patented. Key safety considerations include its half-life of 11 hours. Qulipta is used as a preventive treatment for episodic migraine in adults.
At a glance
| Generic name | ATOGEPANT |
|---|---|
| Sponsor | AbbVie |
| Drug class | Calcitonin Gene-related Peptide Receptor Antagonist [EPC] |
| Target | Calcitonin gene-related peptide type 1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2021 |
| Annual revenue | 201 |
Mechanism of action
Atogepant is calcitonin gene-related peptide (CGRP) receptor antagonist.
Approved indications
- Preventive treatment of migraine
Common side effects
- Nausea
- Constipation
- Fatigue/Somnolence
- Decreased Appetite
- Liver Enzyme Elevations
- Weight Decrease
- Transaminase Elevations
Key clinical trials
- Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine (PHASE3)
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (PHASE3)
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study (PHASE4)
- Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (PHASE3)
- Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years (PHASE3)
- Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
- Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Qulipta CI brief — competitive landscape report
- Qulipta updates RSS · CI watch RSS
- AbbVie portfolio CI